The primary objective of Phase II trials is to assess the treatment's efficacy, usually measured by the tumor response rate, progression-free survival, or overall survival. Secondary objectives often include further evaluating safety and side effects, as well as exploring biomarkers that may predict the treatment's effectiveness.